Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy.

Anderson AM, Easley KA, Kasher N, Franklin D, Heaton RK, Zetterberg H, Blennow K, Gisslen M, Letendre SL.

J Neurovirol. 2018 Aug 13. doi: 10.1007/s13365-018-0664-y. [Epub ahead of print]

PMID:
30105502
2.

Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden.

de Coninck Z, Hussain-Alkhateeb L, Bratt G, Ekström AM, Gisslén M, Petzold M, Svedhem V.

AIDS Patient Care STDS. 2018 Aug;32(8):297-305. doi: 10.1089/apc.2018.0015.

3.

Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.

Ulfhammer G, Edén A, Mellgren Å, Fuchs D, Zetterberg H, Hagberg L, Nilsson S, Yilmaz A, Gisslén M.

AIDS. 2018 Sep 24;32(15):2171-2178. doi: 10.1097/QAD.0000000000001950.

PMID:
30005007
4.

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group.

J Infect Dis. 2018 Oct 5;218(10):1523-1530. doi: 10.1093/infdis/jiy399.

PMID:
29982509
5.

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.

Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S.

Br J Clin Pharmacol. 2018 Jun;84(6):1380-1383. doi: 10.1111/bcp.13552. Epub 2018 Mar 15.

PMID:
29444348
6.

Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?

Burbelo PD, Price RW, Hagberg L, Hatano H, Spudich S, Deeks SG, Gisslén M.

J Infect Dis. 2018 Mar 13;217(7):1024-1032. doi: 10.1093/infdis/jix662.

7.

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.

Sörstedt E, Carlander C, Flamholc L, Hejdeman B, Svedhem V, Sönnerborg A, Gisslén M, Yilmaz A.

Int J Antimicrob Agents. 2018 May;51(5):733-738. doi: 10.1016/j.ijantimicag.2018.01.009. Epub 2018 Jan 31.

PMID:
29371105
8.

Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden.

Andersson E, Nordquist A, Esbjörnsson J, Flamholc L, Gisslén M, Hejdeman B, Marrone G, Norrgren H, Svedhem V, Wendahl S, Albert J, Sönnerborg A.

AIDS. 2018 Apr 24;32(7):877-884. doi: 10.1097/QAD.0000000000001763.

PMID:
29369826
9.

Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017.

Navér L, Albert J, Carlander C, Flamholc L, Gisslén M, Karlström O, Svedhem-Johansson V, Sönnerborg A, Westling K, Yilmaz A, Pettersson K.

Infect Dis (Lond). 2018 Jul;50(7):495-506. doi: 10.1080/23744235.2018.1428825. Epub 2018 Jan 24. Review.

PMID:
29363407
10.

Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers.

van Zoest RA, Underwood J, De Francesco D, Sabin CA, Cole JH, Wit FW, Caan MWA, Kootstra NA, Fuchs D, Zetterberg H, Majoie CBLM, Portegies P, Winston A, Sharp DJ, Gisslén M, Reiss P; Comorbidity in Relation to AIDS (COBRA) Collaboration .

J Infect Dis. 2017 Dec 27;217(1):69-81. doi: 10.1093/infdis/jix553.

11.

Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden.

Neogi U, Siddik AB, Kalaghatgi P, Gisslén M, Bratt G, Marrone G, Sönnerborg A.

Sci Rep. 2017 Jul 25;7(1):6371. doi: 10.1038/s41598-017-06860-2.

12.

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.

Häggblom A, Santacatterina M, Neogi U, Gisslen M, Hejdeman B, Flamholc L, Sönnerborg A.

PLoS One. 2017 Jul 20;12(7):e0180140. doi: 10.1371/journal.pone.0180140. eCollection 2017.

13.

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.

Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslén M, Björkman P.

PLoS One. 2017 Jul 6;12(7):e0180761. doi: 10.1371/journal.pone.0180761. eCollection 2017.

14.

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid.

Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Garagnani P, Pirazzini C, Franceschi C, Fuchs D, Gisslén M, Winston A, Reiss P, Kootstra NA; Comorbidity in Relation to AIDS (COBRA) Collaboration .

Open Forum Infect Dis. 2017 May 25;4(3):ofx108. doi: 10.1093/ofid/ofx108. eCollection 2017 Summer.

15.

Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls.

Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gisslén M.

Expert Rev Mol Diagn. 2017 Aug;17(8):761-770. doi: 10.1080/14737159.2017.1341313. Epub 2017 Jun 14. Review.

PMID:
28598205
16.

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S.

J Infect Dis. 2017 Apr 1;215(7):1132-1140. doi: 10.1093/infdis/jix013.

17.

Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway.

Portelius E, Mattsson N, Pannee J, Zetterberg H, Gisslén M, Vanderstichele H, Gkanatsiou E, Crespi GA, Parker MW, Miles LA, Gobom J, Blennow K.

Mol Neurodegener. 2017 Feb 20;12(1):18. doi: 10.1186/s13024-017-0152-5.

18.

HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.

Häggblom A, Lindbäck S, Gisslén M, Flamholc L, Hejdeman B, Palmborg A, Leval A, Herweijer E, Valgardsson S, Svedhem V.

PLoS One. 2017 Feb 16;12(2):e0171227. doi: 10.1371/journal.pone.0171227. eCollection 2017.

19.

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

Anesten B, Yilmaz A, Hagberg L, Zetterberg H, Nilsson S, Brew BJ, Fuchs D, Price RW, Gisslén M.

Neurol Neuroimmunol Neuroinflamm. 2016 Nov 9;3(6):e300. eCollection 2016 Dec.

20.

Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.

Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JL, Chalermchai T, Krebs SJ, Robb ML, Hellmuth J, Gisslén M, Zetterberg H, Spudich S; RV254SEARCH 010, RV304SEARCH 013, and SEARCH 011 Study Teams.

AIDS. 2017 Jan 14;31(2):247-252. doi: 10.1097/QAD.0000000000001314.

21.

Antiretroviral treatment for HIV infection: Swedish recommendations 2016.

Eriksen J, Albert J, Blaxhult A, Carlander C, Flamholc L, Gisslén M, Josephson F, Karlström O, Navér L, Svedhem V, Yilmaz A, Sönnerborg A.

Infect Dis (Lond). 2017 Jan;49(1):1-34. Epub 2016 Nov 2.

PMID:
27804313
22.

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

Edén A, Nilsson S, Hagberg L, Fuchs D, Zetterberg H, Svennerholm B, Gisslén M.

J Infect Dis. 2016 Dec 15;214(12):1822-1825. Epub 2016 Sep 28.

PMID:
27683820
23.

Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.

Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, Gabuzda D, Gisslen M, Beth Joseph S, Letendre S, Mukerji SS, Nath A, Perez-Valero I, Persaud D, Price RW, Rao VR, Sacktor N, Swanstrom R, Winston A, Wojna V, Wright E, Spudich S.

J Virus Erad. 2016 Oct 5;2(4):243-250.

24.

HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries.

Esbjörnsson J, Mild M, Audelin A, Fonager J, Skar H, Bruun Jørgensen L, Liitsola K, Björkman P, Bratt G, Gisslén M, Sönnerborg A, Nielsen C; SPREAD/ESAR Programme, Medstrand P, Albert J.

Virus Evol. 2016 Apr 27;2(1):vew010. eCollection 2016 Jan.

25.

Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets.

Gisslén M, Svedhem V, Lindborg L, Flamholc L, Norrgren H, Wendahl S, Axelsson M, Sönnerborg A.

HIV Med. 2017 Apr;18(4):305-307. doi: 10.1111/hiv.12431. Epub 2016 Aug 18.

26.

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.

Ahlgren E, Hagberg L, Fuchs D, Andersson LM, Nilsson S, Zetterberg H, Gisslén M.

PLoS One. 2016 Jul 21;11(7):e0158973. doi: 10.1371/journal.pone.0158973. eCollection 2016.

27.

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Krut JJ, Price RW, Zetterberg H, Fuchs D, Hagberg L, Yilmaz A, Cinque P, Nilsson S, Gisslén M.

Virulence. 2017 Jul 4;8(5):599-604. doi: 10.1080/21505594.2016.1212155. Epub 2016 Jul 19.

28.

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.

Ferretti F, Bigoloni A, Passeri L, Galli L, Longo V, Gerevini S, Spagnuolo V, Gisslen M, Zetterberg H, Fuchs D, Cattaneo D, Caramatti G, Lazzarin A, Cinque P, Castagna A.

Medicine (Baltimore). 2016 Jul;95(28):e4144. doi: 10.1097/MD.0000000000004144.

29.

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.

Sörstedt E, Nilsson S, Blaxhult A, Gisslén M, Flamholc L, Sönnerborg A, Yilmaz A.

BMC Infect Dis. 2016 Jun 21;16:305. doi: 10.1186/s12879-016-1628-6.

30.

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H.

EBioMedicine. 2016 May;7:287-288. doi: 10.1016/j.ebiom.2016.04.021. Epub 2016 Apr 20. No abstract available.

31.

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Edén A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, Franklin D, Price RW, Grant I, Letendre SL, Gisslén M.

PLoS One. 2016 Jun 13;11(6):e0157160. doi: 10.1371/journal.pone.0157160. eCollection 2016.

32.

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.

Jespersen S, Pedersen KK, Anesten B, Zetterberg H, Fuchs D, Gisslén M, Hagberg L, Trøseid M, Nielsen SD.

BMC Infect Dis. 2016 Apr 21;16:176. doi: 10.1186/s12879-016-1510-6.

33.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

PMID:
27090986
34.

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H.

EBioMedicine. 2015 Nov 22;3:135-140. doi: 10.1016/j.ebiom.2015.11.036. eCollection 2016 Jan.

35.

HIV-1 low copy viral sequencing-A prototype assay.

Mellberg T, Krabbe J, Gisslén M, Svennerholm B.

Infect Dis (Lond). 2016;48(6):472-6. doi: 10.3109/23744235.2015.1133925. Epub 2016 Jan 14.

PMID:
26763384
36.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

37.

Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.

Karlsson U, Repits J, Antonsson L, Cederfjäll E, Ljungberg B, Ålenius M, Sabirsh A, Gisslen M, Esbjörnsson J, Jansson M.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):e79-82. doi: 10.1097/QAI.0000000000000873. No abstract available.

38.

Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.

Gaines H, Albert J, Axelsson M, Berglund T, Gisslén M, Sönnerborg A, Blaxhult A, Bogdanovic G, Brytting M, Carlander C, Flamholc L, Follin P, Haggar A, Hagstam P, Johansson M, Navér L, Persson Blom J, Samuelson A, Ström H, Sundqvist M, Svedhem Johansson V, Tegmark Wisell K, Tegnell A, Thorstensson R.

Infect Dis (Lond). 2016 Feb;48(2):93-8. doi: 10.3109/23744235.2015.1089593. Epub 2015 Sep 28. Review.

PMID:
26414596
39.

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease.

Mäkitalo S, Mellgren Å, Borgh E, Kilander L, Skillbäck T, Zetterberg H, Gisslén M.

AIDS Res Ther. 2015 Jul 14;12:23. doi: 10.1186/s12981-015-0063-x. eCollection 2015.

40.

Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.

Peluso MJ, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Fletcher JL, Lerdlum S, Chomchey N, Slike B, Sailasuta N, Gisslén M, Zetterberg H, Spudich S; RV254/SEARCH 010 and SEARCH 011 Study Teams.

J Infect Dis. 2015 Dec 1;212(11):1759-67. doi: 10.1093/infdis/jiv296. Epub 2015 May 20.

41.

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Ferretti F, Gisslen M, Cinque P, Price RW.

Curr HIV/AIDS Rep. 2015 Jun;12(2):280-8. doi: 10.1007/s11904-015-0267-7. Review.

PMID:
25860317
42.

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.

Di Yacovo MS, Moltó J, Ferrer E, Curran A, Else L, Gisslén M, Clotet B, Tiraboschi JM, Niubò J, Vila A, Zetterberg H, Back D, Podzamczer D.

J Antimicrob Chemother. 2015 May;70(5):1513-6. doi: 10.1093/jac/dku558. Epub 2015 Jan 20.

PMID:
25608583
43.

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, Yiannoutsos CT, Spudich SS, Price RW.

PLoS One. 2014 Dec 26;9(12):e116081. doi: 10.1371/journal.pone.0116081. eCollection 2014.

44.

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.

Suh J, Sinclair E, Peterson J, Lee E, Kyriakides TC, Li FY, Hagberg L, Fuchs D, Price RW, Gisslen M, Spudich S.

J Neuroinflammation. 2014 Dec 3;11:199. doi: 10.1186/s12974-014-0199-y.

45.

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.

Albert J, Berglund T, Gisslén M, Gröön P, Sönnerborg A, Tegnell A, Alexandersson A, Berggren I, Blaxhult A, Brytting M, Carlander C, Carlson J, Flamholc L, Follin P, Haggar A, Hansdotter F, Josephson F, Karlström O, Liljeros F, Navér L, Pettersson K, Johansson VS, Svennerholm B, Tunbäck P, Widgren K.

Scand J Infect Dis. 2014 Oct;46(10):673-7. doi: 10.3109/00365548.2014.926565. Epub 2014 Jul 30. Review.

46.

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW.

AIDS. 2014 Sep 24;28(15):2251-8. doi: 10.1097/QAD.0000000000000400.

47.

Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades.

Neogi U, Häggblom A, Santacatterina M, Bratt G, Gisslén M, Albert J, Sonnerborg A.

PLoS One. 2014 Jun 12;9(6):e99390. doi: 10.1371/journal.pone.0099390. eCollection 2014.

48.

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.

Navér L, Albert J, Böttiger Y, Carlander C, Flamholc L, Gisslén M, Josephson F, Karlström O, Lindborg L, Svedhem-Johansson V, Svennerholm B, Sönnerborg A, Yilmaz A, Pettersson K.

Scand J Infect Dis. 2014 Jun;46(6):401-11. doi: 10.3109/00365548.2014.898333. Epub 2014 Apr 22. Review.

PMID:
24754479
49.

Treatment of HIV in the Central Nervous System.

Yilmaz A, Gisslén M.

Semin Neurol. 2014 Feb;34(1):14-20. doi: 10.1055/s-0034-1372338. Epub 2014 Apr 8. Review.

PMID:
24715484
50.

Evolving character of chronic central nervous system HIV infection.

Price RW, Spudich SS, Peterson J, Joseph S, Fuchs D, Zetterberg H, Gisslén M, Swanstrom R.

Semin Neurol. 2014 Feb;34(1):7-13. doi: 10.1055/s-0034-1372337. Epub 2014 Apr 8. Review.

Supplemental Content

Loading ...
Support Center